| Abstrakt: |
A recent study conducted by researchers at Beijing University of Chinese Medicine explores the potential of bile acids (BAs) as antiviral drugs. The study focuses on chenodeoxycholic acid (CDCA) and its receptor, farnesoid X receptor (FXR), which negatively regulates interferon signaling and limits the effectiveness of CDCA in inhibiting virus replication. The researchers found that FXR deficiency or pharmacological inhibition enhances interferon signaling activation, leading to a more potent ability of CDCA to restrict virus infection. These findings suggest that targeting FXR inhibition could be a promising strategy for the clinical application of BAs metabolites as antiviral drugs. [Extracted from the article] |
